We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Original Investigation | Epidemiology

Serum Carboxymethyllysine, an Advanced Glycation End Product, and Age-Related Macular Degeneration:  The Age, Gene/Environment Susceptibility–Reykjavik Study

Richard D. Semba, MD1; Mary Frances Cotch, PhD2; Vilmundur Gudnason, MD, PhD3,4; Gudny Eiríksdottir, MSc3; Tamara B. Harris, MD5; Kai Sun, MS1; Ronald Klein, MD6; Fridbert Jonasson, MD4,7; Luigi Ferrucci, MD, PhD8; Debra A. Schaumberg, ScD, OD, MPH9
[+] Author Affiliations
1Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland
2Division of Epidemiology and Clinical Research, National Eye Institute, Bethesda, Maryland
3Icelandic Heart Association, Reykjavik, Iceland
4Department of Medicine, University of Iceland, Reykjavik, Iceland
5Laboratory of Epidemiology, Demography, and Biometry, Intramural Research Program, National Institute on Aging, Bethesda, Maryland
6Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison
7Department of Ophthalmology, Landspitali University Hospital, Reykjavik, Iceland
8Longitudinal Studies Section, National Institute on Aging, Baltimore, Maryland
9Moran Center for Translational Medicine, Department of Ophthalmology and Visual Sciences, University of Utah School of Medicine, Salt Lake City
JAMA Ophthalmol. 2014;132(4):464-470. doi:10.1001/jamaophthalmol.2013.7664.
Text Size: A A A
Published online

Importance  Advanced glycation end products have been implicated in the pathogenesis of age-related macular degeneration (AMD).

Objective  To investigate the relationship between serum carboxymethyllysine (CML), a major circulating advanced glycation end product, and AMD in older adults.

Design, Setting, and Participants  Cross-sectional study of a population-based sample of 4907 older adults (aged ≥66 years) in the Age, Gene/Environment Susceptibility–Reykjavik Study in Iceland.

Exposures  Serum CML and risk factors for AMD.

Main Outcomes and Measures  Early or late AMD, assessed through fundus images taken through dilated pupils using a 45° digital camera and grading for drusen size, type, area, increased retinal pigment, retinal pigment epithelial depigmentation, neovascular lesions, and geographic atrophy using the modified Wisconsin Age-Related Maculopathy Grading System.

Results  Of the 4907 participants, 1025 (20.9%) had early AMD and 276 (5.6%) had late AMD. Mean (SD) serum CML concentrations among adults with no AMD, early AMD, and late AMD (exudative AMD and pure geographic atrophy) were 618.8 (195.5), 634.2 (206.4), and 638.4 (192.0) ng/mL, respectively (to convert to micromoles per liter, multiply by 0.00489; P = .07). Log serum CML (per 1-SD increase) was not associated with any AMD (early and late AMD) (odds ratio = 0.97; 95% CI, 0.90-1.04; P = .44) or with late AMD (odds ratio = 0.94; 95% CI, 0.82-1.08; P = .36) in respective multivariable logistic regression models adjusting for age, sex, body mass index, smoking, and renal function.

Conclusions and Relevance  Higher serum CML concentration had no significant cross-sectional association with prevalent AMD in this large population-based cohort of older adults in Iceland.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 1

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles